AI assistant
LIGAND PHARMACEUTICALS INC — Director's Dealing 2015
Jun 12, 2015
31289_dirs_2015-06-11_77534c57-a129-4c4b-8568-534eaa511c92.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2015-06-09
Reporting Person: HIGGINS JOHN L (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2015-06-09 | Common Stock | S | 6200 | $92.53 | Disposed | 129844 | Direct |
| 2015-06-09 | Common Stock | S | 3300 | $93.21 | Disposed | 126544 | Direct |
| 2015-06-09 | Common Stock | S | 500 | $95.06 | Disposed | 126044 | Direct |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.00 to $92.96, inclusive. The reporting person undertakes to provide, upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.00 to $93.52, inclusive.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.67 to $95.26, inclusive.